

type of report	Current report
number	29/2012
company	PHARMENA

### May 2012 monthly report

The Management Board of Pharmena S.A. hereby presents its monthly report for May 2012:

#### 1. Information on trends and events occurring in the Issuer's market environment

To the best knowledge of the Management Board, in May 2012 no trends or events occurred in the Issuer's market environment which could significantly influence financial results of the company.

In May 2012, Pharmena S.A. developed its network of sales and carried out marketing actions in order to increase sales profit from its marketed products. In order to achieve that, a cooperation with Hebe – health and beauty chain stores was commenced. This is the part of Issuer's strategy pursuing expansion of distribution channels by entering health and beauty stores.

In May 2012, the Company published its Q1 2012 quarterly report. During the reported period, the Issuer gained operating profit in the amount of 452,527.62 PLN (in 2011 this profit equalled to 262,476.14 PLN) and net profit in the amount of 320,822.59 PLN (in 2011 this profit equalled to 194,932.41 PLN). Intensive sales growth conjunct with keeping marketing expenditure at the last year's level, and lower costs of production resulting from a change of manufacturing localisation are factors which had the most significant influence on the results achieved by the Company in Q1 2012. Thus, there was a significant increase in the profitability of sales, operating activities and net profit. These are the reasons why the Company marks such a rapid development.

On 14<sup>th</sup> May 2012, Ordinary General Meeting of Shareholders took place, which adopted, among others, a resolution no. 4 on the following distribution of 2011 profit:

- a) for dividend – the amount of 312,713 PLN (say: three hundred twelve thousand seven hundred and thirteen PLN 00/100), i.e. 0.05 PLN per share,
- b) for supplementary capital – the amount of 296,284.21 PLN (say: two hundred ninety-six thousand two hundred eighty-four PLN 21/100).

It was decided that:

- a) a dividend per 1 (one) share equals to gross 0.05 PLN,
- b) the right to dividend date is established for 14<sup>th</sup> June 2012,
- c) Shareholders holding shares at the end of the day indicated in point b.) will be entitled to the right to dividend,
- d) dividend payment date is established for 5<sup>th</sup> July 2012.

Also, pursuant to resolution no. 16, adopted on 14<sup>th</sup> May 2012 during Ordinary General Meeting of Shareholders of Pharmena S.A. on Company's share capital increase through issue of series C bearer shares, with no pre-emptive rights, the Issuer commenced public offering of series C shares.

The goal of the issue is to obtain funds for further clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA.

The acquisition of shares offering will be addressed exclusively to investors of the Management Board's choice, who are either qualified investors or investors each of whom acquires securities of a value, calculated on the basis of the issue price or selling price, of at least 50,000 EUR for the day on which that price is defined, pursuant to Art. 7 (3.1, 3.2) of act on public offering, conditions governing the introduction of financial instruments to organised trading, and public companies dated July 29<sup>th</sup> 2005 (Dz. U. 2009, No. 185, item 1439, with further amendments) within private placement (Art. 431 (2.1) Code of Commercial Companies – KSH).

In May 2012, the Company continued its research and development work on new products and searched for new applications for active substances protected by patents and patent applications owned by the Company.

Within the project concerning innovative anti-atherosclerosis medicinal product 1-MNA, the Company commissioned production of tablets containing active substance 1-MNA. The production of tablets is indispensable for further clinical trials.

#### 2. Achievement of the goals of an issue

In May 2012, Pharmena S.A. did not make any money expenditure directly on issue-related purposes. However, a subsidiary company Cortria Corporation spent in May 2012 its funds on preparing patent application and formulation of tablets.

#### 3. A list of all information published by the Issuer in the form of current reports in the reporting period from 1<sup>st</sup> May

2012 to 31<sup>st</sup> May 2012

During the period covered by this report, Pharmena S.A. published the following reports in EBI system:

Current report no. 19/2012 of 11<sup>th</sup> May 2012 – April 2012 monthly report

Current report no. 20/2012 of 14<sup>th</sup> May 2012 – Q1 2012 quarterly report

Current report no. 21/2012 of 15<sup>th</sup> May 2012 - Resolutions adopted during Ordinary General Meeting of Shareholders of PHARMENA S.A.

Current report no. 22/2012 of 15<sup>th</sup> May 2012 – Dividend payment for 2011

Current report no. 23/2012 of 15<sup>th</sup> May 2012 – Commencing cooperation with Hebe

Current report no. 24/2012 of 16<sup>th</sup> May 2012 – Termination of agreement with Authorised Counselling Agency

Current report no. 25/2012 of 17<sup>th</sup> May 2012 – Public offering of series C shares

Current report no. 26/2012 of 30<sup>th</sup> May 2012 – Order for production of tablets within the 1-MNA project

During the period covered by this report, Pharmena S.A. published the following reports in ESPI system:

Current report no. 03/2012 of 16<sup>th</sup> May 2012 – A list of shareholders possessing 5 or more per cent of voting power during Ordinary General Meeting of Shareholders of 14<sup>th</sup> May 2012

4. Investor's calendar for June 2012

Publication of June 2012 monthly report until 14<sup>th</sup> July 2012

Legal basis: Resolution No. 795/2008 of the Warsaw Stock Exchange Management Board dated 31<sup>st</sup> November 2008 concerning the adoption of the codes of best practice applicable on the NewConnect market, Appendix 1, point 16.

**Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board